Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NOVAFED vs ADVIL ALLERGY SINUS
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Novafed contains pseudoephedrine, a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors in the respiratory tract mucosa, causing vasoconstriction and reducing nasal congestion.
Pseudoephedrine is a sympathomimetic amine that directly stimulates alpha-adrenergic receptors, causing vasoconstriction of nasal mucosa and sinus vessels. Chlorpheniramine is an alkylamine antihistamine that competitively antagonizes histamine H1 receptors, reducing allergic symptoms. Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, decreasing prostaglandin synthesis and reducing pain, fever, and inflammation.
FDA: Relief of nasal congestion due to common cold, hay fever, or other respiratory allergies,Off-label: Sinus congestion, eustachian tube congestion
Temporary relief of nasal congestion, sinus pressure, sneezing, runny nose, itchy/watery eyes, and headache due to colds or allergies,Fever reduction,Minor aches and pains
1-2 capsules orally every 12 hours; each capsule contains pseudoephedrine HCl 120 mg and dextromethorphan HBr 30 mg.
1-2 tablets (each tablet contains ibuprofen 200 mg and pseudoephedrine HCl 30 mg) orally every 4-6 hours as needed; maximum 6 tablets per day.
Terminal elimination half-life: 4-8 hours (mean 5-6 hours); prolonged in renal impairment (up to 20 hours) and with urinary alkalinization; in patients with normal renal function, steady-state is achieved after 2-3 days of every-6-hour dosing.
2–4 hours (pseudoephedrine: 5–8 hours); clinical context: requires q4-6h dosing for pain/fever, q6-8h for congestion
Pseudoephedrine is partially metabolized in the liver by N-demethylation to an inactive metabolite. It is excreted primarily unchanged in urine (70-90%).
Ibuprofen: Primarily hepatic via CYP2C9; Pseudoephedrine: Hepatic via N-demethylation and oxidative metabolism; Chlorpheniramine: Hepatic via CYP2D6 and CYP3A4.
Renal elimination of unchanged drug and metabolites; approximately 60-70% of a dose is excreted in urine as unchanged pseudoephedrine within 24 hours; the remainder is metabolized hepatically and excreted renally; minimal biliary/fecal elimination (<5%).
Renal (90% as conjugates and metabolites; <10% unchanged); biliary/fecal (<5%)
Approximately 20-25% bound to plasma proteins (mainly albumin).
Ibuprofen: >99% (albumin); pseudoephedrine: <20% (albumin)
Apparent volume of distribution (Vd): 2.5-3.5 L/kg; indicates extensive tissue distribution (e.g., into respiratory mucosa, CNS); Vd is increased in obesity.
Ibuprofen: 0.1–0.2 L/kg; pseudoephedrine: 2.5–3.5 L/kg (extensive tissue distribution)
Oral bioavailability: approximately 100% for immediate-release tablets; pseudoephedrine is well absorbed with high systemic availability; extended-release forms have similar extent of absorption but with slower rate.
Ibuprofen: 80–100% oral; pseudoephedrine: >90% oral
Cr Cl 30-50 m L/min: administer every 12 hours; Cr Cl 10-29 m L/min: administer every 24 hours; Cr Cl <10 m L/min: not recommended.
If GFR <30 m L/min: avoid use of ibuprofen component; pseudoephedrine dose interval may need to be increased (every 8-12 hours) due to reduced clearance.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: administer every 12 hours; Child-Pugh Class C: not recommended.
Child-Pugh Class A: no adjustment; Class B: use with caution, maximum ibuprofen dose 1200 mg/day; Class C: contraindicated due to risk of hepatotoxicity and renal impairment.
Children 6-12 years: 1/2 capsule orally every 12 hours; children <6 years: not recommended.
Not recommended for children under 12 years of age; for children ≥12 years: same as adult dose (200 mg ibuprofen/30 mg pseudoephedrine) every 4-6 hours, maximum 6 tablets per day.
Initiate at lower end of dosing range (1 capsule every 12 hours) due to increased sensitivity and potential for adverse effects; monitor renal function.
Initiate at lowest effective dose (1 tablet every 6-8 hours); monitor renal function and blood pressure due to increased risk of GI bleeding, cardiovascular events, and pseudoephedrine-induced hypertension.
No FDA black box warning.
No FDA black box warning exists for this combination product. However, NSAIDs like ibuprofen carry a black box warning for increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal, especially with prolonged use or in patients with cardiovascular risk factors.
Use with caution in patients with hypertension, cardiovascular disease, diabetes, glaucoma, hyperthyroidism, prostatic hypertrophy, and in elderly. May cause insomnia, nervousness, and elevated blood pressure.
Cardiovascular risk: NSAIDs increase risk of serious cardiovascular events. Gastrointestinal risk: NSAIDs can cause bleeding, ulceration, and perforation. Hypertension: Pseudoephedrine may elevate blood pressure. Avoid use with MAOIs or within 14 days of stopping. Caution in hyperthyroidism, diabetes, glaucoma, prostatic hypertrophy, and renal impairment.
Severe hypertension, severe coronary artery disease, narrow-angle glaucoma, urinary retention, concurrent use of MAO inhibitors or within 14 days of stopping, and hypersensitivity to pseudoephedrine.
Hypersensitivity to any component; Concurrent MAOI therapy; Severe hypertension or coronary artery disease; Active peptic ulcer disease; History of aspirin/NSAID-induced asthma; Pregnancy (especially third trimester); Children under 12 years (per product labeling).
Avoid concurrent use with caffeinated beverages or foods as they may increase nervousness and insomnia. Alcohol should be avoided as it can exacerbate side effects. No significant food-drug interactions with other items.
Avoid alcohol due to increased risk of GI bleeding and liver toxicity. No known food interactions with chlorpheniramine or pseudoephedrine. Taking with food may reduce gastric irritation from ibuprofen.
First trimester: Inadequate human data; animal studies show no teratogenicity at therapeutic doses. Second/third trimester: Potential for uterine artery vasoconstriction reducing placental perfusion; risk of fetal tachycardia. Avoid in pregnancy unless benefit outweighs risk.
First trimester: NSAIDs are associated with increased risk of miscarriage and congenital malformations (cardiac defects, gastroschisis). Third trimester: Risk of premature closure of ductus arteriosus, oligohydramnios, and necrotizing enterocolitis. Avoid use after 30 weeks gestation.
Pseudoephedrine (active ingredient in NOVAFED) is excreted into breast milk; M/P ratio not determined. May reduce milk production. Use with caution; monitor infant for irritability and sleep disturbances.
Ibuprofen and pseudoephedrine are excreted into breast milk. Ibuprofen has low milk/plasma ratio (0.01-0.07) and is generally considered compatible. Pseudoephedrine may reduce milk production and cause irritability in infants. Use with caution, especially in preterm infants.
No specific dose adjustment recommended; use lowest effective dose and shortest duration. Increased plasma volume in pregnancy may reduce drug levels but no data to support dose increase due to potential maternal-fetal risks.
No specific dose adjustments recommended for pregnancy; however, use the lowest effective dose for the shortest duration. Avoid in third trimester. Pseudoephedrine dose remains standard; caution in hypertensive disorders.
NOVAFED contains pseudoephedrine and is contraindicated in patients with severe hypertension or coronary artery disease. Monitor blood pressure closely. Onset of action is 30-60 minutes; do not exceed 240 mg/day. Avoid use with MAOIs or within 14 days of stopping them.
Advil Allergy Sinus contains ibuprofen (NSAID), chlorpheniramine (first-generation antihistamine), and pseudoephedrine (decongestant). Avoid in patients with aspirin/NSAID allergy, severe hypertension, coronary artery disease, or MAOI use. Caution in elderly due to anticholinergic effects. Pseudoephedrine may cause insomnia and anxiety; avoid evening dosing.
Do not crush or chew extended-release tablets.,Stop use if you experience rapid heartbeat, dizziness, or difficulty urinating.,Avoid taking close to bedtime to prevent insomnia.,Do not take with other cold or allergy medications containing decongestants.,Consult a doctor if symptoms persist after 7 days or are accompanied by fever.
Do not take if allergic to aspirin or NSAIDs.,Avoid alcohol to reduce risk of stomach bleeding.,Do not use with other products containing NSAIDs or decongestants.,May cause drowsiness; avoid driving or operating machinery.,Do not take for more than 10 days for pain or 3 days for fever.,Consult a doctor if you have high blood pressure, heart disease, glaucoma, or an enlarged prostate.,Pseudoephedrine may cause difficulty sleeping; take last dose at least 4-6 hours before bedtime.,Take with food or milk to minimize stomach upset.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NOVAFED vs ADVIL ALLERGY SINUS, answered by our medical review team.
NOVAFED is a Decongestant that works by Novafed contains pseudoephedrine, a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors in the respiratory tract mucosa, causing vasoconstriction and reducing nasal congestion.. ADVIL ALLERGY SINUS is a NSAID/Decongestant/Antihistamine Combination that works by Pseudoephedrine is a sympathomimetic amine that directly stimulates alpha-adrenergic receptors, causing vasoconstriction of nasal mucosa and sinus vessels. Chlorpheniramine is an alkylamine antihistamine that competitively antagonizes histamine H1 receptors, reducing allergic symptoms. Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, decreasing prostaglandin synthesis and reducing pain, fever, and inflammation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NOVAFED and ADVIL ALLERGY SINUS depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NOVAFED is: 1-2 capsules orally every 12 hours; each capsule contains pseudoephedrine HCl 120 mg and dextromethorphan HBr 30 mg.. The standard adult dose of ADVIL ALLERGY SINUS is: 1-2 tablets (each tablet contains ibuprofen 200 mg and pseudoephedrine HCl 30 mg) orally every 4-6 hours as needed; maximum 6 tablets per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NOVAFED and ADVIL ALLERGY SINUS in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NOVAFED is classified as Category C. First trimester: Inadequate human data; animal studies show no teratogenicity at therapeutic doses. Second/third trimester: Potential for uterine artery vasoconstriction reducing p. ADVIL ALLERGY SINUS is classified as Category C. First trimester: NSAIDs are associated with increased risk of miscarriage and congenital malformations (cardiac defects, gastroschisis). Third trimester: Risk of premature closure . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.